Literature DB >> 12186920

In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.

Yubin Kang1, Colleen S Stein, Jason A Heth, Patrick L Sinn, Andrea K Penisten, Patrick D Staber, Kenneth L Ratliff, Hong Shen, Carrie K Barker, Inês Martins, C Matthew Sharkey, David Avram Sanders, Paul B McCray, Beverly L Davidson.   

Abstract

Vectors derived from lentiviruses provide a promising gene delivery system. We examined the in vivo gene transfer efficiency and tissue or cell tropism of a feline immunodeficiency virus (FIV)-based lentiviral vector pseudotyped with the glycoproteins from Ross River Virus (RRV). RRV glycoproteins were efficiently incorporated into FIV virions, generating preparations of FIV vector, which after concentration attain titers up to 1.5 x 10(8) TU/ml. After systemic administration, RRV-pseudotyped FIV vectors (RRV/FIV) predominantly transduced the liver of recipient mice. Transduction efficiency in the liver with the RRV/FIV was ca. 20-fold higher than that achieved with the vesicular stomatitis virus G protein (VSV-G) pseudotype. Moreover, in comparison to VSV-G, the RRV glycoproteins caused less cytotoxicity, as determined from the levels of glutamic pyruvic transaminase and glutamic oxalacetic transaminase in serum. Although hepatocytes were the main liver cell type transduced, nonhepatocytes (mainly Kupffer cells) were also transduced. The percentages of the transduced nonhepatocytes were comparable between RRV and VSV-G pseudotypes and did not correlate with the production of antibody against the transgene product. After injection into brain, RRV/FIV preferentially transduced neuroglial cells (astrocytes and oligodendrocytes). In contrast to the VSV-G protein that targets predominantly neurons, <10% of the brain cells transduced with the RRV pseudotyped vector were neurons. Finally, the gene transfer efficiencies of RRV/FIV after direct application to skeletal muscle or airway were also examined and, although transgene-expressing cells were detected, their proportions were low. Our data support the utility of RRV glycoprotein-pseudotyped FIV lentiviral vectors for hepatocyte- and neuroglia-related disease applications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186920      PMCID: PMC136422          DOI: 10.1128/jvi.76.18.9378-9388.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Efficient gene delivery into adult cardiomyocytes by recombinant Sindbis virus.

Authors:  D A Dätwyler; H M Eppenberger; D Koller; J E Bailey; J P Magyar
Journal:  J Mol Med (Berl)       Date:  1999-12       Impact factor: 4.599

2.  The use of a recombinant lentiviral vector for ex vivo gene transfer into the rat CNS.

Authors:  U Englund; C Ericson; C Rosenblad; R J Mandel; D Trono; K Wictorin; C Lundberg
Journal:  Neuroreport       Date:  2000-12-18       Impact factor: 1.837

3.  Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors.

Authors:  Colleen S Stein; Beverly L Davidson
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

4.  VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.

Authors:  N J DePolo; J D Reed; P L Sheridan; K Townsend; S L Sauter; D J Jolly; T W Dubensky
Journal:  Mol Ther       Date:  2000-09       Impact factor: 11.454

5.  Increasing epithelial junction permeability enhances gene transfer to airway epithelia In vivo.

Authors:  G Wang; J Zabner; C Deering; J Launspach; J Shao; M Bodner; D J Jolly; B L Davidson; P B McCray
Journal:  Am J Respir Cell Mol Biol       Date:  2000-02       Impact factor: 6.914

6.  Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus.

Authors:  R Berkowitz; H Ilves; W Y Lin; K Eckert; A Coward; S Tamaki; G Veres; I Plavec
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Efficient lentiviral transduction of liver requires cell cycling in vivo.

Authors:  F Park; K Ohashi; W Chiu; L Naldini; M A Kay
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

8.  Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect.

Authors:  G Wang; V Slepushkin; J Zabner; S Keshavjee; J C Johnston; S L Sauter; D J Jolly; T W Dubensky; B L Davidson; P B McCray
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

9.  Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production.

Authors:  C M Sharkey; C L North; R J Kuhn; D A Sanders
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Evaluation of recombinant alphaviruses as vectors in gene therapy.

Authors:  J J Wahlfors; S A Zullo; S Loimas; D M Nelson; R A Morgan
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

View more
  34 in total

1.  Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells.

Authors:  Mingjie Li; Nada Husic; Ying Lin; Heather Christensen; Ibrahim Malik; Sally McIver; Christine M LaPash Daniels; David A Harris; Paul T Kotzbauer; Mark P Goldberg; B Joy Snider
Journal:  J Neurosci Methods       Date:  2010-03-27       Impact factor: 2.390

2.  Optimization of feline immunodeficiency virus vectors for RNA interference.

Authors:  Scott Q Harper; Patrick D Staber; Christine R Beck; Sarah K Fineberg; Colleen Stein; Dalyz Ochoa; Beverly L Davidson
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

4.  A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

Authors:  Hideto Matsui; Carol Hegadorn; Margareth Ozelo; Erin Burnett; Angie Tuttle; Andrea Labelle; Paul B McCray; Luigi Naldini; Brian Brown; Christine Hough; David Lillicrap
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

5.  Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins.

Authors:  Andrey A Kolokoltsov; Scott C Weaver; Robert A Davey
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

7.  Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases.

Authors:  Laetitia P L Pelascini; Ignazio Maggio; Jin Liu; Maarten Holkers; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Hum Gene Ther Methods       Date:  2013-10-29       Impact factor: 2.396

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 9.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

Review 10.  Human gene therapy vectors derived from feline lentiviruses.

Authors:  Román A Barraza; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.